Shares of Puma Biotechnology Inc (NYSE:PBYI) have been assigned a consensus recommendation of “Buy” from the eleven analysts that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $111.11.

PBYI has been the subject of a number of research reports. Zacks Investment Research raised shares of Puma Biotechnology from a “hold” rating to a “buy” rating and set a $36.00 target price for the company in a report on Tuesday, May 16th. Stifel Nicolaus reissued a “buy” rating and issued a $88.00 price objective on shares of Puma Biotechnology in a research note on Monday, May 22nd. Citigroup Inc. reissued a “buy” rating and issued a $88.00 price objective on shares of Puma Biotechnology in a research note on Monday, May 22nd. Cowen and Company reissued a “market perform” rating on shares of Puma Biotechnology in a research note on Monday, May 22nd. Finally, Credit Suisse Group set a $58.00 price objective on shares of Puma Biotechnology and gave the stock a “buy” rating in a research note on Monday, May 22nd.

Puma Biotechnology (NYSE:PBYI) traded down 2.93% on Friday, reaching $104.25. 850,226 shares of the company were exchanged. Puma Biotechnology has a 12-month low of $28.35 and a 12-month high of $109.85. The firm has a 50-day moving average of $88.39 and a 200 day moving average of $63.61. The firm’s market capitalization is $3.88 billion.

Puma Biotechnology (NYSE:PBYI) last announced its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($2.10) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.32) by $0.78. On average, equities analysts predict that Puma Biotechnology will post ($8.60) earnings per share for the current year.

In other Puma Biotechnology news, insider Alan H. Auerbach sold 13,175 shares of the stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $94.73, for a total transaction of $1,248,067.75. Following the completion of the transaction, the insider now owns 4,170,623 shares in the company, valued at $395,083,116.79. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Richard Paul Bryce sold 15,000 shares of the stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $100.09, for a total transaction of $1,501,350.00. Following the transaction, the senior vice president now owns 28,239 shares of the company’s stock, valued at approximately $2,826,441.51. The disclosure for this sale can be found here. Insiders have sold 282,433 shares of company stock valued at $23,233,612 over the last ninety days. 22.70% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently added to or reduced their stakes in the business. Bank of Montreal Can lifted its position in Puma Biotechnology by 1.8% during the second quarter. Bank of Montreal Can now owns 5,351 shares of the biopharmaceutical company’s stock valued at $468,000 after purchasing an additional 97 shares during the last quarter. Ameritas Investment Partners Inc. lifted its position in Puma Biotechnology by 5.9% during the second quarter. Ameritas Investment Partners Inc. now owns 2,522 shares of the biopharmaceutical company’s stock valued at $220,000 after purchasing an additional 140 shares during the last quarter. Legal & General Group Plc lifted its position in Puma Biotechnology by 2.8% during the first quarter. Legal & General Group Plc now owns 9,297 shares of the biopharmaceutical company’s stock valued at $346,000 after purchasing an additional 249 shares during the last quarter. Rhumbline Advisers lifted its position in Puma Biotechnology by 0.8% during the second quarter. Rhumbline Advisers now owns 33,733 shares of the biopharmaceutical company’s stock valued at $2,948,000 after purchasing an additional 271 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in Puma Biotechnology by 2.0% during the second quarter. The Manufacturers Life Insurance Company now owns 22,299 shares of the biopharmaceutical company’s stock valued at $1,950,000 after purchasing an additional 437 shares during the last quarter. Institutional investors and hedge funds own 80.98% of the company’s stock.

WARNING: This story was reported by American Banking News and is owned by of American Banking News. If you are reading this story on another website, it was copied illegally and reposted in violation of US and international copyright & trademark legislation. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/09/09/puma-biotechnology-inc-pbyi-receives-average-recommendation-of-buy-from-brokerages.html.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Analyst Recommendations for Puma Biotechnology (NYSE:PBYI)

Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.